Andrew P. Mazar - Publications, H-index & Citations

Andrew P. Mazar

actuate therapeutics inc

59H指数

417论文数

9.9K被引数

收录论文 105

发表时间

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial Elraglusib与化疗在转移性胰腺导管腺癌中的应用：一项随机对照二期临床试验

Nature Medicine

IF50

2026-04-14

OAAI

Devalingam Mahalingam; Rachna T. Shroff; Benedito A. Carneiro; Yan Ji; Andrew L. Coveler; Andres Cervantes; Vaibhav Sahai; Anne Ploquin; Sandrine Hiret; Noelle K. LoConte; Ivor J. Percent; Charles D. Lopez; Simon Pernot; Petr Kavan; Mary Mulcahy; Ryan Carr; Francis J. Giles; Chris Seifarth; Andrey Ugolkov; Taylor Weiskittel; Gil Fine; Mark Jaros; Andrew P. Mazar; Tanios S. Bekaii-Saab

uPAR deficiency triggers TGFβ1-mediated fibrotic remodeling in a cardiac perivascular-like microenvironment uPAR缺陷在类血管周微环境中触发TGFβ1介导的纤维化重塑。

Stem Cell Research & Therapy

IF7.3

2026-02-13

OAAI

Yulia Goltseva; Zoya Tsokolaeva; Irina Beloglazova; Victoria Stepanova; Maria Boldyreva; Elizaveta Ratner; Andrew Mazar; Alexander Andreev; Andrey Shiryaev; Yelena Parfyonova; Konstantin Dergilev

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer II期研究评估elraglusib（9-ING-41），一种GSK-3β抑制剂，与吉西他滨联合nab-紫杉醇用于既往未治疗的转移性胰腺癌。

ESMO Open

IF8.3

2025-06-01

OAAI

D. Mahalingam; A. Saeed; S.F. Powell; M. Huerta; V. Sahai; A.L. Coveler; E.J. Davis; N. Steeghs; M. Mulcahy; A.G. Raufi; L. Cavalcante; A. Cervantes; J. Berlin; T. Weisskittel; A. Ugolkov; A.P. Mazar; W. Mikrut; S. Smith; F.J. Giles; B.A. Carneiro

Targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells

SCIENTIFIC REPORTS

IF3.9

2024-09-17

OAAI

Markovska, A.; Somers, K.; Guillaume, J.; Melief, J.; Mazar, A. P.; Schmitt, D. M.; Schipper, H. S.; Boes, M.

Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer 儿童和青少年癌症PI3-K、mTOR、AKT和GSK3β 抑制剂药物开发儿科战略论坛

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-08-01

PREAI

Pearson, Andrew D. J.; DuBois, Steven G.; Macy, Margaret E.; de Rojas, Teresa; Donoghue, Martha; Weiner, Susan; Knoderer, Holly; Bernardi, Ronald; Buenger, Vickie; Canaud, Guillaume; Cantley, Lewis; Chung, John; Fox, Elizabeth; Friend, John; Glade-Bender, Julia; Gorbatchevsky, Igor; Gore, Lia; Gupta, Abha; Hawkins, Douglas S.; Juric, Dejan; Lang, Leigh Anna; Leach, Danielle; Liaw, Danny; Lesa, Giovanni; Ligas, Franca; Lindberg, Gavin; Lindberg, Wendy; Ludwinski, Donna; Marshall, Lynley; Mazar, Andrew; McDonough, Joe; Nysom, Karsten; Urs, Christopher O.; Pappo, Alberto; Parsons, D. William; Rosenfeld, Amy; Scobie, Nicole; Smith, Malcolm; Taylor, Danielle; Weigel, Brenda; Weinstein, Amy; Karres, Dominik; Vassal, Gilles

Glycogen synthase kinase 3 activity enhances liver in flammation in MASH 糖原合酶激酶3活性增强了糖化醪中肝脏的燃烧

JHEP REPORTS

IF7.5

2024-06-01

OAAI

Khoury, Mireille; Guo, Qianqian; Furuta, Kunimaro; Correia, Cristina; Meroueh, Chady; Lee, Hyun Se Kim; Warasnhe, Khaled; Valenzuela-Perez, Lucia; Mazar, Andrew P.; Kim, Iljung; Noh, Yung-Kyun; Holmes, Heather; Romero, Michael F.; Sussman, Caroline R.; Pavelko, Kevin D.; Islam, Shahidul; Bamidele, Adebowale O.; Hirsova, Petra; Ibrahim, Samar H.

Identification of potential immune biomarkers for GSK-3 inhibitor elraglusib (9-ING-41) in patients with relapsed/refractory metastatic cancer

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Weiskittel, Taylor; Huntington, Kelsey; Zhang, Leiqing; Koukol, Austin; Carneiro, Benedito A.; Li, Hu; Ugolkov, Andrey; El-Deiry, Wafik; Mazar, Andrew

Genome wide CRISPR/Cas9 library screening identifies aurora kinase A as a regulator of elraglusib sensitivity in pancreatic cancer

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Ding, Li; Maeder, Easton; Zhang, Cheng; Weiskittel, Taylor; Schmitt, Daniel; Mazar, Andrew; Li, Hu; Billadeau, Daniel

Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial

CANCER RESEARCH

IF16.6

2023-04-14

PREAI

Weiskittel, Taylor; McDermott, Joseph; Billadeau, Daniel; Li, Hu; Saeed, Anwaar; Mahalingam, Devalingam; Sahebjam, Solmaz; Munster, Pamela; Cavalcante, Ludimila; Giles, Frank J.; Mazar, Andrew; Carneiro, Benedito

Exploring mechanisms of resistance to elraglusib in pancreatic cancer PDX models

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Weiskittel, Taylor; Li, Ding; Han, Lingling; McDermott, Joseph; Caneiro, Benedito; Li, Hu; Billadeau, Daniel; Mazar, Andrew

Elraglusib response prediction and mechanistic discovery using iterative machine learning

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

McDermott, Joseph; Weiskittel, Taylor; Billadeau, Daniel; Carneiro, Benedito; Li, Hu; Mazar, Andrew

Regulation of urokinase receptor expression by p53: Novel role in stabilization of uPAR mRNA

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-04-01

OAAI

Shetty, Sreerama; Velusamy, Thirunavukkarasu; Idell, Steven; Shetty, Praveenkumar; Mazar, Andrew P.; Bhandary, Yashodhar P.; Shetty, Rashmi S.

PET in vivo generators 134Ce and 140Nd on an internalizing monoclonal antibody probe

SCIENTIFIC REPORTS

IF3.9

2022-03-09

OAAI

Severin, G. W.; Fonslet, J.; Kristensen, L. K.; Nielsen, C. H.; Jensen, A., I; Kjaer, A.; Mazar, A. P.; Johnston, K.; Koster, U.

Genomic biomarkers for response to 9-ING-41, a small molecule selective glycogen synthase kinase-3 (GSK-3) inhibitor, in pancreas cancer: Preliminary results

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-12-01

PREAI

Borden, Brittany A.; De Souza, Andre; Mahalingam, Devalingam; Powell, Steven; Munster, Pamela N.; Huntington, Kelsey; Mazar, Andrew; Calvacante, Ludmila; Giles, Francis J.; El-Deiry, Wafik S.; Safran, Howard P.; Carneiro, Benedito A.

Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors

MOLECULAR IMAGING AND BIOLOGY

IF2.5

2021-10-12

OAAI

Baart, Victor M.; van Manen, Labrinus; Bhairosingh, Shadhvi S.; Vuijk, Floris A.; Iamele, Luisa; de Jonge, Hugo; Scotti, Claudia; Resnati, Massimo; Cordfunke, Robert A.; Kuppen, Peter J. K.; Mazar, Andrew P.; Burggraaf, Jacobus; Vahrmeijer, Alexander L.; Sier, Cornelis F. M.

Rationale and design of the phase IIb/III VOICE trial of clonidine MBT for the prevention of severe oral mucositis in patients with OPC receiving chemoradiotherapy

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Mazar, A. P.; Robinson, C. D.; Starr, C. M.; Layton, G.; Rioux, P.

More on the Source of D-Dimer in COVID-19

THROMBOSIS AND HAEMOSTASIS

IF4.3

2021-06-25

OAAI

Kwaan, Hau C.; Mazar, Andrew P.

A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma

EUROPEAN JOURNAL OF CANCER

IF7.1

2021-03-01

OAAI

Baart, Victor M.; van der Horst, Geertje; Deken, Marion M.; Bhairosingh, Shadhvi S.; Schomann, Timo; Sier, Vincent Q.; van der Mark, Maaike H.; Iamele, Luisa; de Jonge, Hugo; Resnati, Massimo; Mazar, Andrew P.; Pelger, Rob C. M.; van der Pluijm, Gabriel; Kuppen, Peter J. K.; Vahrmeijer, Alexander L.; Sier, Cornelis F. M.

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-01-05

OAAI

Borden, Brittany A.; Baca, Yasmine; Xiu, Joanne; Tavora, Fabio; Winer, Ira; Weinberg, Benjamin A.; Vanderwalde, Ari M.; Darabi, Sourat; Korn, W. Michael; Mazar, Andrew P.; Giles, Francis J.; Crawford, Lorin; Safran, Howard; El-Deiry, Wafik S.; Carneiro, Benedito A.

Glycogen synthase kinase-3 beta (GSK-3b) genomic alterations and increased programmed death-ligand 1 (PD-L1) expression in advanced malignancies

CANCER RESEARCH

IF16.6

2020-08-15

PREAI

Borden, Brittany A.; Xiu, Joanne; Baca, Yasmine; Ramos, Pilar; Giles, Francis J.; Mazar, Andrew; Tavora, Fabio; Safran, Howard; El-Deiry, Wafik S.; Carneiro, Benedito A.

研究方向